Lack of p53 nuclear immunostaining is not indicative of absence of TP53 gene mutations in colorectal adenocarcinomas

Anna Colomer,1 Nadina Erill,1 Montse Verdú,2 Ruth Roman,1 August Vidal,1,2 Carlos Cordon-Cardo,1,3 Xavier Puig1,2

1BIOPAT, Grup Assistència, Barcelona; 2HISTOPAT Laboratoris, Barcelona; and 3Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York.

Multiple studies using primary tumors have reported that alterations in p53 expression and detection of TP53 mutations are associated with clinical aggressiveness and poor response to specific therapies.  However, there is no general agreement regarding the optimal technical approach to the analysis of p53.  We have studied a series of […]

2003-07-23T16:51:27+00:00

Molecular evaluation of TP53 status in human colorectal and urinary bladder cancer: phenotype versus genotype analysis

Erill N1, Colomer A1, Verdú M2, Román R1, Vidal A2, Condom E2, Banús JM3, Cordón-Cardo C1,2, Puig X1,2.

1BIOPAT. Grup Assistència, 2HISTOPAT Laboratoris & 3ICUN. Institut Català d’Urologia i Nefrologia. Barcelona (Spain).

Mutations of the TP53 tumor suppressor gene and nuclear accumulation of abnormal p53 proteins are common in colon and bladder cancer, and have been associated with clinical aggressiveness and poor response to specific therapies. However, there is no general agreement regarding the optimal technical approach to define the TP53 status […]

2003-02-23T16:49:37+00:00

MSI status modulates the value of some molecular markers in colorectal tumors

 A. Colomer, N. Erill, M. Verdú, R. Román, A Vidal, X. Puig.

BIOPAT. Biopatologia Molecular, SL. Barcelona, Spain.

 

LOH 17p/TP53 and LOH 18q/DCC have been related to prognosis of colorectal adenocarcinomas. Since MSI-H tumors have a minor rate of TP53 mutations and rarely present allelic deletions, we intended to study these molecular features in a series of 197 primary tumors previously categorized for MSI status. Eighteen tumors out of 181 (10%) exhibited MSI-H. p53 alterations were approached by a combination of […]

2002-02-09T22:12:42+00:00

TP53, 17P and 18Q alterations as prognostic markers in MSS colorectal adenocarcinomas

Anna Colomer1, Nadina Erill1, Montse Verdú2, Ruth Román1, August Vidal1,2, Xavier Puig1,2.

1BIOPAT, Biopatologia Molecular, Barcelona, Spain. 2Histopat Laboratoris, Barcelona, Spain.

Two different patterns have been described for colorectal tumorigenesis. The main one -affecting 85% of sporadic tumors- is based on the familial adenomatous polyposis (FAP) model, a multistep process that involves at least APC, K-RASDCC andTP53 genes. The second pathway shares its etiology with hereditary non-polyposis colorectal cancer (HNPCC), and is characterized by mutations at the mismatch repair genes (MMR) that lead […]

2002-02-09T22:11:46+00:00